SKYE
Skye Bioscience, Inc.
Price Chart
Latest Quote
$0.71
-0.00 (-0.59%)
Current Price
| Previous Close | $0.71 |
| Open | $0.73 |
| Day High | $0.75 |
| Day Low | $0.70 |
| Volume | 119,839 |
Stock Information
| Shares Outstanding | 35.14M |
| Total Debt | $311K |
| Cash Equivalents | $17.11M |
| Net Income | $-57.33M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $24.86M |
| EPS (TTM) | $-1.45 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $8.45M |
| Income | $-57.33M |
| Book/sh | $0.26 |
| Cash/sh | $0.49 |
| Employees | 12 |
Financial Ratios
| Quick Ratio | 1.64 |
| Current Ratio | 1.78 |
| Debt/Eq | 3.46 |
Returns & Margins
| ROA | -87.70% |
| ROE | -167.97% |
Ownership
| Insider Ownership | 1.17% |
| Institutional Ownership | 46.00% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -0.63 |
| P/B | 2.75 |
Analyst Data
| Recommendation | none |
| Target Price | $7.71 |
Technical Indicators
| SMA20 | $0.77 |
| SMA50 | $0.81 |
| SMA200 | $1.33 |
| RSI | 40.61 |
| ATR | 0.0632 |
| Shares Float | 22.96M |
| Short Float | 4.50% |
| Short Ratio | 6.69 |
| Rel Volume | 0.80 |
Performance History
| Week | -11.62% |
| Month | -2.48% |
| Quarter | +7.94% |
| 6 Months | -40.59% |
| YTD | -19.48% |
| Year | -65.85% |
| 3 Years | -82.32% |
| 5 Years | -98.23% |
| 10 Years | -99.48% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $0.71 | 157,200 |
| 2026-06-17 | $0.71 | 78,300 |
| 2026-06-16 | $0.72 | 209,500 |
| 2026-06-15 | $0.73 | 186,200 |
| 2026-06-12 | $0.79 | 121,800 |
| 2026-06-11 | $0.80 | 337,400 |
| 2026-06-10 | $0.78 | 138,200 |
| 2026-06-09 | $0.75 | 203,200 |
| 2026-06-08 | $0.77 | 133,900 |
| 2026-06-05 | $0.73 | 169,800 |
| 2026-06-04 | $0.77 | 295,600 |
| 2026-06-03 | $0.77 | 168,600 |
| 2026-06-02 | $0.71 | 353,000 |
| 2026-06-01 | $0.76 | 145,000 |
| 2026-05-29 | $0.77 | 451,600 |
| 2026-05-28 | $0.85 | 120,100 |
| 2026-05-27 | $0.83 | 98,000 |
| 2026-05-26 | $0.82 | 133,700 |
| 2026-05-22 | $0.83 | 233,400 |
| 2026-05-21 | $0.71 | 179,800 |
| 2026-05-20 | $0.77 | 89,800 |
| 2026-05-19 | $0.73 | 134,200 |
About Skye Bioscience, Inc.
Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. is headquartered in San Diego, California.
đ° Latest News
Halozyme Therapeutics Touts $1.8B Revenue Outlook, ENHANZE Royalties and New Hypercon Deals at Conference
MarketBeat âĸ 2026-03-18T05:06:57Z
Skye Bioscience Inc (SKYE) Q4 2025 Earnings Call Highlights: Pioneering Advances in Obesity ...
GuruFocus.com âĸ 2026-03-12T01:04:48ZCompanies Like Skye Bioscience (NASDAQ:SKYE) Could Be Quite Risky
Simply Wall St. âĸ 2026-01-12T11:45:53Z
A Look At Halozyme Therapeutics (HALO) Valuation After New ENHANZE Obesity Partnership With Skye Bioscience
Simply Wall St. âĸ 2026-01-07T13:12:24Z
Skye Bioscience Inc (SKYE) Q3 2025 Earnings Call Highlights: Promising Study Results and ...
GuruFocus.com âĸ 2025-11-11T05:01:38Z
Why Skye Bioscience (SKYE) Is Down 51.0% After Releasing Phase 2a Nimacimab Trial Results and What's Next
Simply Wall St. âĸ 2025-10-07T13:22:25Z
Top Midday Decliners
MT Newswires âĸ 2025-10-06T17:27:03ZSkye shares crash as obesity drug falls short in key study
BioPharma Dive âĸ 2025-10-06T10:09:00Z
Could This New Drug Be The Safer Way To Fight Obesity?
Benzinga âĸ 2025-09-19T18:19:20Z
Skye Bioscience Inc (SKYE) Q2 2025 Earnings Call Highlights: Promising Trial Progress Amid ...
GuruFocus.com âĸ 2025-08-08T11:00:42Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $0 | $967,602 | $897,207 | $663,774 |
| Total Expenses | $58,163,565 | $36,427,435 | $13,671,801 | $12,106,422 |
| Other Income Expense | $360,248 | $7,590,929 | $-23,163,087 | $-6,602,089 |
| Other Non Operating Income Expenses | $-502 | $-2,200 | $-1,383,282 | - |
| Net Non Operating Interest Income Expense | $1,883,903 | $2,279,454 | $-806,296 | $-766,350 |
| Interest Expense Non Operating | $0 | $967,602 | $897,207 | $663,774 |
| Operating Expense | $58,163,565 | $36,427,435 | $13,671,801 | $12,106,422 |
| General And Administrative Expense | $15,801,686 | $17,725,741 | $7,852,340 | $6,094,617 |
| Total Other Finance Cost | - | $16,456 | $9,063 | $121,587 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-55,924,814 | $-26,567,123 | $-37,644,784 | $-19,481,602 |
| Net Interest Income | $1,883,903 | $2,279,454 | $-806,296 | $-766,350 |
| Interest Income | $1,883,903 | $3,263,512 | $99,974 | $19,011 |
| Normalized Income | $-56,209,806 | $-32,565,695 | $-20,438,738 | $-14,265,952 |
| Net Income From Continuing And Discontinued Operation | $-55,924,814 | $-26,567,123 | $-37,644,784 | $-19,481,602 |
| Total Operating Income As Reported | $-58,163,565 | $-30,192,718 | $-34,735,173 | $-18,311,732 |
| Net Income Common Stockholders | $-55,924,814 | $-26,567,123 | $-37,644,784 | $-19,481,602 |
| Net Income | $-55,924,814 | $-26,567,123 | $-37,644,784 | $-19,481,602 |
| Net Income Including Noncontrolling Interests | $-55,924,814 | $-26,567,123 | $-37,644,784 | $-19,481,602 |
| Net Income Continuous Operations | $-55,924,814 | $-26,567,123 | $-37,644,784 | $-19,481,602 |
| Pretax Income | $-55,919,414 | $-26,557,052 | $-37,641,184 | $-19,474,861 |
| Special Income Charges | $360,750 | $7,593,129 | $-21,779,805 | $-6,661,818 |
| Interest Income Non Operating | $1,883,903 | $3,263,512 | $99,974 | $19,011 |
| Operating Income | $-58,163,565 | $-36,427,435 | $-13,671,801 | $-12,106,422 |
| Per Share | ||||
| Diluted EPS | $-1.41 | $-0.73 | $-5.37 | $-8.77 |
| Basic EPS | $-1.41 | $-0.73 | $-5.37 | $-8.77 |
| Other | ||||
| Tax Effect Of Unusual Items | $75,758 | $1,594,557 | $-4,573,759 | $-1,386,439 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-55,556,812 | $-32,883,939 | $-14,839,921 | $-12,094,000 |
| Total Unusual Items | $360,750 | $7,593,129 | $-21,779,805 | $-6,602,089 |
| Total Unusual Items Excluding Goodwill | $360,750 | $7,593,129 | $-21,779,805 | $-6,602,089 |
| Reconciled Depreciation | $723,352 | $298,640 | $124,251 | $114,998 |
| EBITDA (Bullshit earnings) | $-55,196,062 | $-25,290,810 | $-36,619,726 | $-18,696,089 |
| EBIT | $-55,919,414 | $-25,589,450 | $-36,743,977 | $-18,811,087 |
| Diluted Average Shares | $39,662,664 | $36,486,519 | $7,006,038 | $2,221,080 |
| Basic Average Shares | $39,662,664 | $36,486,519 | $7,006,038 | $2,221,080 |
| Diluted NI Availto Com Stockholders | $-55,924,814 | $-26,567,123 | $-37,644,784 | $-19,481,602 |
| Tax Provision | $5,400 | $10,071 | $3,600 | $6,741 |
| Gain On Sale Of Ppe | $360,750 | $1,358,412 | $-307,086 | $0 |
| Research And Development | $42,361,879 | $18,701,694 | $5,819,461 | $6,011,805 |
| Selling General And Administration | $15,801,686 | $17,725,741 | $7,852,340 | $6,094,617 |
| Other Gand A | $15,801,686 | $17,725,741 | $7,852,340 | $6,094,617 |
| Gain On Sale Of Business | - | $0 | $-409,347 | $-456,508 |
| Other Special Charges | - | $-6,234,717 | $21,063,372 | $6,205,310 |
| Restructuring And Mergern Acquisition | - | - | $409,347 | $456,508 |
| Gain On Sale Of Security | - | - | $3 | $59,729 |
| Write Off | - | - | - | $456,508 |
Fetched: 2026-06-19
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $20,024,175 | $68,151,724 | $-2,131,818 | $-3,008,054 |
| Total Assets | $28,313,633 | $72,763,773 | $11,940,411 | $9,111,072 |
| Total Non Current Assets | $1,219,486 | $1,936,526 | $289,568 | $167,354 |
| Other Non Current Assets | $53,910 | $53,910 | $8,309 | $8,309 |
| Current Assets | $27,094,147 | $70,827,247 | $11,650,843 | $8,943,718 |
| Other Current Assets | $13,781 | $207,205 | $558,248 | $306,081 |
| Prepaid Assets | $1,332,671 | $2,199,236 | $597,698 | $882,193 |
| Receivables | $10,474 | $5,065 | $158,242 | $74,121 |
| Taxes Receivable | $10,474 | $5,065 | $158,242 | $74,121 |
| Cash Cash Equivalents And Short Term Investments | $25,737,221 | $68,415,741 | $1,256,453 | $1,244,527 |
| Cash And Cash Equivalents | $5,882,498 | $68,415,741 | $1,256,453 | $1,244,527 |
| Restricted Cash | - | $0 | $9,080,202 | $4,580 |
| Assets Held For Sale Current | - | - | $0 | $6,432,216 |
| Cash Financial | - | - | $1,256,453 | $1,244,527 |
| Debt | ||||
| Total Debt | $273,646 | $455,590 | $4,615,266 | $1,982,526 |
| Long Term Debt And Capital Lease Obligation | $83,999 | $273,162 | $171,230 | $0 |
| Current Debt And Capital Lease Obligation | $189,647 | $182,428 | $4,444,036 | $1,982,526 |
| Net Debt | - | - | $3,115,545 | $659,299 |
| Current Debt | - | - | $4,371,998 | $1,903,826 |
| Other Current Borrowings | - | - | $4,371,998 | $1,903,826 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $8,289,458 | $4,612,049 | $14,072,229 | $12,119,126 |
| Total Non Current Liabilities Net Minority Interest | $83,999 | $273,162 | $171,230 | $0 |
| Current Liabilities | $8,205,459 | $4,338,887 | $13,900,999 | $12,119,126 |
| Other Current Liabilities | $2,633,918 | $549,149 | $969,615 | $7,482,850 |
| Payables And Accrued Expenses | $5,381,894 | $3,607,310 | $8,487,348 | $2,653,750 |
| Payables | $2,033,431 | $569,252 | $956,754 | $1,890,748 |
| Accounts Payable | $2,033,431 | $569,252 | $956,754 | $1,794,898 |
| Interest Payable | - | $0 | $360,777 | $15,814 |
| Other Payable | - | - | - | $55,451 |
| Equity | ||||
| Common Stock Equity | $20,024,175 | $68,151,724 | $-2,131,818 | $-3,008,054 |
| Total Equity Gross Minority Interest | $20,024,175 | $68,151,724 | $-2,131,818 | $-3,008,054 |
| Stockholders Equity | $20,024,175 | $68,151,724 | $-2,131,818 | $-3,008,054 |
| Retained Earnings | $-186,874,486 | $-130,949,672 | $-104,382,549 | $-66,737,765 |
| Other | ||||
| Ordinary Shares Number | $33,378,139 | $30,974,559 | $12,349,243 | $3,654,115 |
| Share Issued | $33,378,139 | $30,974,559 | $12,349,243 | $3,654,115 |
| Tangible Book Value | $20,024,175 | $68,151,724 | $-2,131,818 | $-3,008,054 |
| Invested Capital | $20,024,175 | $68,151,724 | $2,240,180 | $-1,104,228 |
| Working Capital | $18,888,688 | $66,488,360 | $-2,250,156 | $-3,175,408 |
| Capital Lease Obligations | $273,646 | $455,590 | $243,268 | $78,700 |
| Total Capitalization | $20,024,175 | $68,151,724 | $-2,131,818 | $-3,008,054 |
| Additional Paid In Capital | $206,865,282 | $199,070,421 | $102,238,382 | $63,726,057 |
| Capital Stock | $33,379 | $30,975 | $12,349 | $3,654 |
| Common Stock | $33,379 | $30,975 | $12,349 | $3,654 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $83,999 | $273,162 | $171,230 | $0 |
| Current Capital Lease Obligation | $189,647 | $182,428 | $72,038 | $78,700 |
| Current Accrued Expenses | $3,348,463 | $3,038,058 | $7,530,594 | $763,002 |
| Net PPE | $1,165,576 | $1,882,616 | $281,259 | $159,045 |
| Accumulated Depreciation | $-773,647 | $-233,513 | $-95,434 | - |
| Gross PPE | $1,939,223 | $2,116,129 | $376,693 | $159,045 |
| Leases | $23,918 | $23,918 | $13,954 | - |
| Other Properties | $266,646 | $449,864 | $237,983 | $71,191 |
| Machinery Furniture Equipment | $1,648,659 | $1,642,347 | $124,756 | - |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $19,854,723 | $0 | - | - |
| Dueto Related Parties Current | - | - | $0 | $95,850 |
| Buildings And Improvements | - | - | $43,276 | $87,854 |
Fetched: 2026-06-19
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-43,068,841 | $-26,841,507 | $-13,964,728 | $-12,772,132 |
| Operating Activities | ||||
| Operating Cash Flow | $-43,062,529 | $-25,237,480 | $-13,952,178 | $-12,744,072 |
| Cash Flow From Continuing Operating Activities | $-43,062,529 | $-25,237,480 | $-13,952,178 | $-12,744,072 |
| Operating Gains Losses | $-360,750 | $-1,347,618 | $21,472,867 | $-59,729 |
| Investing Activities | ||||
| Capital Expenditure | $-6,312 | $-1,604,027 | $-12,550 | $-28,060 |
| Investing Cash Flow | $-19,500,285 | $-245,615 | $6,596,456 | $5,214,395 |
| Cash Flow From Continuing Investing Activities | $-19,500,285 | $-245,615 | $6,596,456 | $5,214,395 |
| Net Other Investing Changes | - | - | $1,076,740 | $5,242,455 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $0 | $83,556,563 | $11,734,947 | $0 |
| Financing Cash Flow | $29,571 | $83,562,181 | $16,443,270 | $-208,794 |
| Cash Flow From Continuing Financing Activities | $29,571 | $83,562,181 | $16,443,270 | $-208,794 |
| Net Common Stock Issuance | $0 | $83,556,563 | $11,734,947 | $0 |
| Common Stock Issuance | $0 | $83,556,563 | $11,734,947 | $0 |
| Net Other Financing Charges | - | - | $-6,026 | - |
| Other | ||||
| Interest Paid Supplemental Data | $0 | $433,336 | $198,352 | $333,547 |
| Income Tax Paid Supplemental Data | $5,400 | $5,200 | $3,600 | $6,741 |
| End Cash Position | $5,882,498 | $68,415,741 | $10,336,655 | $1,249,107 |
| Beginning Cash Position | $68,415,741 | $10,336,655 | $1,249,107 | $8,987,578 |
| Changes In Cash | $-62,533,243 | $58,079,086 | $9,087,548 | $-7,738,471 |
| Proceeds From Stock Option Exercised | $29,571 | $5,618 | $0 | $1,967 |
| Net Investment Purchase And Sale | $-19,854,723 | $0 | - | - |
| Purchase Of Investment | $-19,854,723 | $0 | - | - |
| Net PPE Purchase And Sale | $354,438 | $-245,615 | $5,519,716 | $-28,060 |
| Sale Of PPE | $360,750 | $1,358,412 | $5,532,266 | $0 |
| Purchase Of PPE | $-6,312 | $-1,604,027 | $-12,550 | $-28,060 |
| Change In Working Capital | $4,731,989 | $-2,628,758 | $-469,307 | $-761,904 |
| Change In Other Current Liabilities | $2,126,762 | $-438,793 | $-665,888 | $-1,825,774 |
| Change In Other Current Assets | $1,357,508 | $-1,460,826 | $-488,790 | $112,907 |
| Change In Payables And Accrued Expense | $1,550,647 | $-721,436 | $-109,861 | $953,927 |
| Change In Accrued Expense | $155,219 | $-134,903 | $591,424 | $154,187 |
| Change In Interest Payable | $0 | $-360,777 | $360,777 | $-159,097 |
| Change In Payable | $1,395,428 | $-586,533 | $-701,285 | $799,740 |
| Change In Account Payable | $1,395,428 | $-586,533 | $-701,285 | $799,740 |
| Change In Prepaid Assets | $-302,928 | $-7,703 | $795,232 | $-2,964 |
| Stock Based Compensation | $7,767,694 | $8,317,480 | $987,510 | $629,032 |
| Asset Impairment Charge | $0 | $325,610 | $0 | - |
| Depreciation Amortization Depletion | $723,352 | $298,640 | $124,251 | $114,998 |
| Depreciation And Amortization | $723,352 | $298,640 | $124,251 | $114,998 |
| Net Income From Continuing Operations | $-55,924,814 | $-26,567,123 | $-37,644,784 | $-19,481,602 |
| Repayment Of Debt | - | $0 | $-259,335 | $-891,662 |
| Issuance Of Debt | - | $0 | $4,973,684 | $680,901 |
| Net Issuance Payments Of Debt | - | $0 | $4,714,349 | $-210,761 |
| Net Short Term Debt Issuance | - | $0 | $4,973,684 | $0 |
| Short Term Debt Issuance | - | $0 | $4,973,684 | $0 |
| Net Long Term Debt Issuance | - | $0 | $-259,335 | $-210,761 |
| Long Term Debt Payments | - | $0 | $-259,335 | $-891,662 |
| Other Non Cash Items | - | $-3,635,711 | $1,577,285 | $6,815,133 |
| Net Foreign Currency Exchange Gain Loss | - | $0 | $-45,350 | $0 |
| Gain Loss On Sale Of PPE | - | $0 | $21,215,214 | $0 |
| Short Term Debt Payments | - | - | $-6,026 | $-616,125 |
| Long Term Debt Issuance | - | - | $0 | $680,901 |
| Gain Loss On Investment Securities | - | - | $-3 | $-59,729 |
| Change In Other Working Capital | - | - | - | - |
Fetched: 2026-06-19